Wednesday, July 18, 2018
 
 
Company News: Page (1) of 1 - 01/10/18 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook
Neos Therapeutics to Present Three Posters at the Upcoming American Professional Society of ADHD and Related Disorders (APSARD) Annual Meeting

(January 10, 2018)

DALLAS and FORT WORTH, Texas, Jan. 10, 2018 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (NASDAQ:NEOS), a pharmaceutical company focused on developing, manufacturing, and commercializing innovative extended-release (XR) products using its proprietary modified-release drug delivery and orally disintegrating tablet (ODT) technology platforms, today announced that study findings for two of its Attention Deficit/Hyperactivity Disorder (ADHD) medications, Cotempla XR-ODT™ (methylphenidate) Extended-Release Orally Disintegrating Tablets and Adzenys ER™ (amphetamine) Extended-Release Oral Suspension, will be presented in three posters at the upcoming 2018 Annual Meeting of the American Professional Society of ADHD and Related Disorders (APSARD), on January 12-14, 2018, at the Marriott Wardman Park hotel in Washington D.C.

All three posters will be presented on Saturday, January 13, 2018, during the 12:30 PM – 2:30 PM session:

  • Poster #58: Efficacy, Safety, and Tolerability of an Extended-Release, Orally Disintegrating Methylphenidate Tablet in Children 6–12 Years of Age with ADHD: Open-Label, Dose-Optimization Period Outcomes

    Presenter: Dr. Ann Childress, President, Center for Psychiatry and Behavioral Medicine, Inc.


  • Poster #71: Population Pharmacokinetic-Pharmacodynamic Modeling of a Novel Methylphenidate Extended-Release Orally Disintegrating Tablet in Pediatric Patients with ADHD
    Presenter: Dr. Nathan Teuscher, Vice President of Pharmacometric Solutions, Certara.

  • Poster #68: A Randomized, Open-Label Bioequivalence Study of a New Extended-Release Amphetamine Oral Suspension in Adults
    Presenter: Dr. Carolyn Sikes, Vice President Clinical Affairs, Neos Therapeutics.

“The presentation of these data at APSARD is a great opportunity for Neos to reach the ADHD professional community,” stated Dr. Vipin Garg, President and CEO of Neos Therapeutics. “We are excited to share the results of these studies with mental health experts who are as committed as we are to helping to improve the lives of patients with ADHD.”

IMPORTANT SAFETY INFORMATION for Cotempla XR-ODT

Cotempla XR-ODT is a federally controlled substance (CII) because it can be abused or lead to dependence. Keep in a safe place to protect it from theft. Selling or giving away your Cotempla XR-ODT may cause death or harm to others and is against the law.

Who should not take Cotempla XR-ODT?

Do not give Cotempla XR-ODT to your child if they are:

  • allergic to methylphenidate or any ingredients in Cotempla XR-ODT.
  • taking or has taken an anti-depression medicine called monoamine oxidase inhibitor (MAOI) within the past 14 days.

What is the most important information I should know about Cotempla XR-ODT?

Cotempla XR-ODT can cause serious side effects. Tell your healthcare provider about health conditions, including if your child:

  • has ever abused or been dependent on alcohol, prescription medicines, or street drugs. Cotempla XR-ODT has a high chance for abuse and can cause physical and psychological dependence.
  • has any heart problems, heart defects, high blood pressure, or a family history of these problems. This is important because sudden death has occurred in people with heart problems or defects. Increased blood pressure and heart rate have been reported. Your healthcare provider should check for heart problems prior to prescribing Cotempla XR-ODT and will check your child’s blood pressure and heart rate regularly during treatment.  Call the healthcare provider or go to the nearest hospital emergency room right away if your child has any signs of heart problems such as chest pain, shortness of breath, or fainting while during treatment.
  • has mental problems, or a family history of suicide, bipolar illness, or depression. This is important because the following could occur: new or worse behavior and thought problems, new or worse bipolar illness, new psychotic symptoms (hearing voices, or seeing or believing things that are not real) or new manic symptoms. Call your healthcare provider right away if there are any new or worsening mental symptoms or problems during treatment.
  • develops painful and prolonged erections (priapism). Priapism has happened in males who take products that contain methylphenidate. Get medical help right away if your child develops priapism.
  • has circulation problems in fingers and toes (peripheral vasculopathy, including Raynaud’s phenomenon). Fingers or toes may feel numb, cool, painful, and/or change color from pale, to blue, to red. Tell your healthcare provider if your child has numbness, pain, skin color change, or sensitivity to temperature in their fingers or toes. Call the healthcare provider right away if any signs of unexplained wounds appear on fingers or toes while taking Cotempla XR-ODT.
  • is having slowing of growth (height and weight). Your child should have his or her height and weight checked often while taking Cotempla XR-ODT. Treatment may be stopped if your child is not gaining weight or height.
  • is pregnant or plans to become pregnant. It is not known if Cotempla XR-ODT will harm the unborn baby. If your child becomes pregnant during treatment with Cotempla XR-ODT, talk to your healthcare provider about registering with the National Pregnancy Registry for Psychostimulants.
  • is breastfeeding, or plans to breastfeed. You and your healthcare provider should decide if your child will take Cotempla XR-ODT or breastfeed.
  • takes any medicines, including prescription and over-the-counter medicines (especially for depression, including MAOIs), vitamins, and herbal supplements. Cotempla XR-ODT and some medicines may interact with each other and cause serious side effects, or sometimes the dose of the other medicine will need to be adjusted.

Do not start any new medicine while taking Cotempla XR-ODT without talking to your healthcare provider first.

What should I avoid during treatment with Cotempla XR-ODT?

  • You should avoid drinking alcohol during treatment with Cotempla XR-ODT.

Common side effects of Cotempla XR-ODT include:
Decreased appetite, trouble sleeping, nausea, vomiting, indigestion, stomach pain, weight loss, anxiety, dizziness, irritability, mood swings, increased heart rate, and increased blood pressure.

These are not all the possible side effects of Cotempla XR-ODT. Call your healthcare provider for medical advice about side effects.

What is Cotempla XR-ODT?

Cotempla XR-ODT is a central nervous system (CNS) stimulant prescription medicine used for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children 6 to 17 years of age. Cotempla XR-ODT is a federally controlled substance (CII) because it contains methylphenidate that can be a target for people who abuse prescription medicines or street drugs.  Keep Cotempla XR-ODT in a safe place to protect it from theft. Selling or giving away your Cotempla XR-ODT may cause death or harm to others and is against the law.

For additional safety information, click here for Full Prescribing Information and Medication Guide and discuss with your healthcare provider.

IMPORTANT SAFETY INFORMATION for Adzenys XR-ODT and Adzenys ER

Adzenys XR-ODT and Adzenys ER are federally controlled substances (CII) because they can be abused or lead to dependence. Keep both Adzenys XR-ODT and Adzenys ER in a safe place to prevent misuse and abuse.  Selling or giving away Adzenys XR-ODT or Adzenys ER may harm others and is against the law.

Tell your doctor if you or your child has ever abused or been dependent on alcohol, prescription medicines, or street drugs.

Who should not take Adzenys XR-ODT or Adzenys ER?
Do not take Adzenys XR-ODT or Adzenys ER if you or your child is:

  • allergic to amphetamine or any ingredients in Adzenys XR-ODT or Adzenys ER.
  • taking or has taken an anti-depression medicine called monoamine oxidase inhibitor (MAOI) within the past 14 days.

Adzenys XR-ODT and Adzenys ER are stimulant medicines. Tell your doctor about health conditions, including if:

  • you or your child has any heart problems, heart defects, high blood pressure, or a family history of these problems. This is important because sudden death has occurred in people with heart problems or defects, and sudden death, stroke and heart attack have happened in adults. Your doctor should check for heart problems prior to prescribing either Adzenys XR-ODT or Adzenys ER and will check you or your child’s blood pressure and heart rate during treatment.  Call the doctor right away if you or your child has any signs of heart problems such as chest pain, shortness of breath, or fainting while taking either Adzenys XR-ODT or Adzenys ER.
  • you or your child has mental problems, or a family history of suicide, bipolar illness, or depression. This is important because the following could occur: new or worse behavior and thought problems, new or worse bipolar illness, new psychotic symptoms (hearing voices, believing things that are not true, are suspicious) or new manic symptoms. Call the doctor right away if there are any new or worsening mental symptoms during treatment.
  • you or your child has circulation problems in fingers and toes (peripheral vasculopathy, including Raynaud’s phenomenon). Fingers or toes may feel numb, cool, painful, sensitive to temperature and/or change color from pale, to blue, to red. Call the doctor right away if any signs of unexplained wounds appear on fingers or toes while taking either Adzenys XR-ODT or Adzenys ER.
  • you or your child is having symptoms of serotonin syndrome which may happen when Adzenys XR-ODT or Adzenys ER is taken with certain other medicines and may be life threatening. Call your doctor or go to the nearest hospital emergency room if you have any of the following symptoms: agitation, hallucinations, coma or other changes in mental status, problems controlling your movements or muscle twitching, fast heartbeat, high or low blood pressure, sweating or fever, muscle stiffness or tightness, nausea, vomiting or diarrhea.
  • your child is having slowing of growth (height and weight). Your child should have his or her height and weight checked often while taking either Adzenys XR-ODT or Adzenys ER. The doctor may stop treatment if a problem is found during these check-ups.
  • you or your child has kidney problems. Your doctor may lower the dose.
  • you or your child is, or plans to become pregnant. If you or your child becomes pregnant during treatment with either Adzenys XR-ODT or Adzenys ER, talk to your doctor about registering with the National Pregnancy Registry for Psychostimulants.
  • you or your child is breastfeeding, or plans to breastfeed. You or your child should not breastfeed while taking either Adzenys XR-ODT or Adzenys ER.
  • you or your child takes any medicines, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Adzenys XR-ODT and Adzenys ER and some medicines may interact with each other and cause serious side effects.

Do not start any new medicine while taking either Adzenys XR-ODT or Adzenys ER without talking to your doctor first.

What should I avoid while taking Adzenys XR-ODT or Adzenys ER?

  • drinking alcohol.

Common side effects for Adzenys XR-ODT and Adzenys ER include:

  • Children 6 – 12 Years: Decreased appetite, problems sleeping, stomach pain, extreme mood change, vomiting, nervousness, nausea, and fever.
  • Children 13 – 17 Years: Decreased appetite, problems sleeping, stomach pain and weight loss, and nervousness.
  • Adults: Dry mouth, decreased appetite, problems sleeping, headache, weight loss, nausea, anxiety, restlessness, dizziness, fast heartbeat, diarrhea, weakness, and urinary tract infections.

These are not all the possible side effects of Adzenys XR-ODT and Adzenys ER. Call your doctor for medical advice about side effects.

What are Adzenys XR-ODT and Adzenys ER?

Adzenys XR-ODT and Adzenys ER are central nervous system (CNS) stimulant prescription medicines used for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in people 6 years of age and older. Adzenys XR-ODT and Adzenys ER are federally controlled substances (CII) because they contain amphetamine that can be a target for people who abuse prescription medicines or street drugs.  Keep both Adzenys XR-ODT or Adzenys ER in a safe place to protect it from theft. Selling or giving away your Adzenys XR-ODT or Adzenys ER may cause death or harm to others and is against the law.

"For additional safety information for Adzenys XR-ODT, click here for the Medication Guide and Prescribing Information and discuss with your doctor."

"For additional safety information for Adzenys ER, click here for the Medication Guide and Prescribing Information and discuss with your doctor."

You are encouraged to report negative side effects of prescription drugs to the FDA.  Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

About ADHD

According to the Centers for Disease Control and Prevention, ADHD is one of the most common neurodevelopment disorders of childhood and can continue through adolescence and adulthood.i In fact, ADHD is estimated to affect 5 percent of children and 2.5 percent of adults in the U.S.ii Symptoms include inattentiveness, hyperactivity and impulsiveness. These patterns of behavior are seen in many settings (school, home, work) and can impact performance and relationships.

Stimulant medications such as amphetamine and methylphenidate are first-line pharmacological therapies for treating ADHD, and extended-release formulations of these medications allow for once-daily dosing.iii Most of the existing treatment options are tablets or capsules, which need to be swallowed intact or in some cases sprinkled on certain foods or fluids and ingested immediately.

About Neos Therapeutics

Neos Therapeutics, Inc. (NASDAQ:NEOS) is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its proprietary modified-release drug delivery technology platforms. Adzenys XR-ODT® (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING), Cotempla XR-ODT™ (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING), and Adzenys-ER™ (amphetamine) extended-release oral suspension (see Full Prescribing Information, including Boxed WARNING), all for the treatment of ADHD, are the first three approved products using the Company’s extended-release  technology platform. Additional information about Neos is available at www.neostx.com.

Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for Neos Therapeutics, Inc., including statements about Neos’ future expectations and plans to defend and enforce its intellectual property rights and other statements containing the words "will," "would," "continue," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related governmental approvals of the settlement and license agreement, Neos’ ability to protect its intellectual property rights, uncertainties related to litigation Neos is involved or may become involved, uncertainties inherent in the initiation of future clinical trials, expectations of expanding ongoing clinical trials and other factors discussed in the "Risk Factors" section of Neos’ Annual Report on Form 10-K for the year ended December 31, 2016, which is on file with the SEC, as updated by any subsequently filed SEC filings, including Neos’ Quarterly Reports on Form 10-Q. Any forward-looking statements contained in this press release speak only as of the date hereof, and Neos expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACTS:

Carolyn Sikes
Vice President Clinical Affairs
Neos Therapeutics 
(973) 744-4299
[email protected]

Richard I. Eisenstadt                                     
Chief Financial Officer                                        
Neos Therapeutics                                    
(972) 408-1389                                              
[email protected]

Sarah McCabe
Investor Relations
Stern Investor Relations, Inc.
(212) 362-1200
[email protected]

Adzenys XR-ODT®, Cotempla XR-ODT™ and Adzenys ER™ are trademarks of NEOS Therapeutics, Inc. ©2018 NEOS Therapeutics, Inc. All rights reserved

i Centers for Disease Control. Attention-Deficit/Hyperactivity Disorder (ADHD). Available at http://www.cdc.gov/ncbddd/adhd/facts.html. Accessed January 8, 2018.

ii American Psychiatric Association. (2013) Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Arlington, VA. 

iii Chew RH, Hales RE, Yudofsky SC: What Your Patients Need to Know About Psychiatric Medications, Second Edition. Washington, DC, American Psychiatric Publishing, 2009.


 


Page: 1


Related Keywords:
Related Sites: DMN Newswire ,   HTN - Health Technology Net
Related Newsletter: Tutorial Finder ,   Review Seeker ,   DMN Newswire Newsletter
 
 
 
 
 
 
 
Seniors

Drugs
  • Healthcare IT Market 2018 - 2023 with SWOT Analysis regarding upcoming Changes and Technology Adaptations in Global Healthcare Sector
  • Implantable Medical Devices Market Predicted to be Worth US$ 49.8 Bn by 2024, Says TMR
  • Global Cosmetic Chemicals Industry
  • HMP's 8th Annual Amputation Prevention Symposium Expected to Draw 800 Clinicians to Chicago to Join the CLI Revolution
  • Progressive Care Inc. Announces Month-End Sales Figures Showing Increase in Year-Over-Year Prescriptions Filled in June 2018

    Cancer
  • Camurus Announces PDUFA Date for CAM2038 for the Treatment of Opioid use Disorder
  • Omega-3 Market to Reach US$ 16.37 Bn by 2023, Globally - QYResearch.com
  • Association of Community Cancer Centers and Advisory Board Launch 9th Annual Trends in Cancer Care Survey
  • Small Animal Imaging Market is Estimated to Grow at a Faster Pace With the Significant CAGR During the Forecast Period: Radiant Insights, Inc.
  • Presage Biosciences Closes Series D Financing with Takeda and Celgene, and Announces Appointment of Richard Klinghoffer, PhD as Chief Executive Officer
  •  
     
     
     
     
     





    Our Privacy Policy --- About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines